

# The Nature and Impact of the Use of Dissolvable Tobacco Products on the Public Health

A Compilation of the Materials from the July 21-22, 2011 and January 18-20, 2012 meetings of the Tobacco Products Scientific Advisory Committee

## Table of Contents

### I. Background

A. [Summary of Dissolvable Tobacco Products references](#) from the Family Smoking Prevention and Tobacco Control Act

B. [Charter of the Tobacco Products Scientific Advisory Committee](#)

### II. July 21-22, 2011 Tobacco Products Scientific Advisory Committee (TPSAC)

A. [Federal Register Notice](#)

B. [TPSAC Committee Roster](#)

C. [Meeting Roster](#)

D. [Final Agenda](#)

E. [Background Materials](#)

1. [FDA Summary Memorandum](#)
2. [Dissolvables References](#)
3. [Request to RJR for Information – February 1, 2010](#)
4. [Request to Star for Information – February 1, 2010](#)
5. [DRAFT Questions to Committee on Dissolvables](#)
6. [Request for Information from Industry 904\(b\) \(June 10, 2011\)](#)
7. [Industry Presentation Topics](#)
8. [Federal Register Notice – Request for Comments to Docket](#)
9. [Comments submitted to Docket](#)
10. [Written Public Submissions](#)
11. Submissions from Industry
  - a) [RJR Background Information](#)
  - b) [Star Background Information](#)

F. Presentations from FDA

1. [Dissolvable Tobacco Products- David L. Ashley, Ph.D., Director, Office of Science, FDA/CTP](#)
2. [Process for the Report- Karen Templeton-Somers, Ph.D., Office of Science, FDA/CTP](#)
3. [Dissolvable Tobacco Products- Sarah E. Evans, Ph.D., Office of Science, FDA/CTP](#)

- G. Presentations from the Tobacco Industry
  - 1. Marketing and Consumer Perceptions
    - a) [Star Scientific - Curtis Wright, M.D., M.P.H., Senior Vice President & Clinical Director, Rock Creek Pharmaceuticals](#)
    - b) [R. J. Reynolds Tobacco Company - Aaron P. Williams, Ph.D., Vice President, Smokeless Product Development, R. J. Reynolds](#)
  - 2. Abuse Liability and Health Risks
    - a) [R. J. Reynolds Tobacco Company - Charles D. Garner, Ph.D. Senior Director, Regulatory Oversight, R. J. Reynolds](#)
    - b) [Star Scientific - Curtis Wright, M.D., M.P.H., Senior Vice President & Clinical Director, Rock Creek Pharmaceuticals](#)
  - 3. Initiation and Cessation
    - a) [Star Scientific - Curtis Wright, M.D., M.P.H. Senior Vice President & Clinical Director, Rock Creek Pharmaceuticals](#)
    - b) [R. J. Reynolds Tobacco Company - Geoffrey M. Curtin, Ph.D., Principal Scientist/Director, Regulatory Oversight, R. J. Reynolds](#)

- H. Open Public Hearing
  - 1. [Elaine Keller- The Consumer Advocates for Smoke-free Alternatives Association](#)
  - 2. Wallace Pickworth - Battelle
  - 3. [James E. Dillard, III - Altria Client Services](#)
  - 4. Jonathan Winickoff, MD, FAAP - American Academy of Pediatrics
  - 5. [Gregory N. Connolly, D.M.D., M.P.H.- Harvard School of Public Health](#)

- I. Discussion and Recommendations from July 21-22, 2011 Meeting
  - 1. [Questions for Discussion](#)
  - 2. Transcripts
    - a) [July 21, 2011](#)
    - b) [July 22, 2011](#)
  - 3. [Webcast](#)

- J. [Final Summary Minutes](#)

### III. January 18-20 Tobacco Products Scientific Advisory Committee (TPSAC)

- A. [Federal Register Notice](#)
- B. [TPSAC Committee Roster](#)
- C. [Meeting Roster](#)
- D. [Final Agenda](#)

E. Background Materials

1. [Cover Sheet](#)
2. [FDA Summary Memorandum](#)
3. [Brief Summary of Smoke-Free Laws in Test Markets](#)
4. [Colorado Clean Indoor Air Act](#)
5. [Marion County, Indiana, Code of Ordinances](#)
6. [North Carolina Smoke-Free Restaurants and Bars Law](#)
7. [Ohio Smoking Ban – Revised Code](#)
8. [Oregon Indoor Clean Air Act](#)
9. [Consideration with Regard to TPSAC’s Review of Dissolvable Tobacco Products – Jonathan Samet](#)
10. [Consideration with Regard to TPSAC’s Review of Dissolvable Tobacco Products \(REVISED\) – Jonathan Samet](#)
11. [Proposed Topics for Discussion](#)
12. [Family Smoking Prevention and Tobacco Control Summary for Dissolvables](#)
13. [Bibliography: List of References Related to Dissolvable Tobacco Products](#)
14. [Materials from the July 2011 meeting of the TPSAC](#)
15. [Addendum and Errata Cover Sheet](#)
16. Written Public Submissions

F. Meeting Slides – January 18, 2012

1. [Opening Remarks](#)
2. [The Swedish Tobacco Harm Reduction Experience](#)
3. [Smokeless Tobacco, Cigarettes, and Dual Product Use: Implications for Dissolvable Product Marketing](#)

G. Meeting Slides – January 19, 2012 – morning session

1. [Health Effects of Dissolvable Tobacco Products](#)
2. [Health Effects of Long-term Use of Therapeutic NRT](#)
3. [Toxic and Carcinogenic Constituents in Dissolvable Tobacco Products](#)
4. [Quantitative and Qualitative Analysis of Dissolvable Tobacco Products](#)
5. [Indiana’s Experience: Marketing of Dissolvable Products](#)

H. Meeting Slides – January 19, 2012 – afternoon session

1. [Data on Accidental Ingestions: With Focus on Pediatric Ingestions](#)
2. [CPSC and the Poison Prevention Packaging Act](#)
3. [Review of Peer-Reviewed Literature](#)
4. Review of Industry Documents Regarding Dissolvable Tobacco Products – RTI International
  - a) [Overview](#)
  - b) [Behavioral Effects](#)
  - c) [Health Effects](#)
  - d) [Marketing Research and Marketing Practices](#)
  - e) [Toxicological & Physiological Effects](#)

- I. Open Public Hearing
  - 1. Andrew Wolford
  - 2. Gregory Conley
  - 3. [Chris Proctor, British American Tobacco](#)
  - 4. Bill Godshall, Smokefree Pennsylvania
  - 5. Gilbert Ross, The American Council on Science and Health
  - 6. Scott Ramminger, American Wholesale Marketers Association
  - 7. Scott Ballin
  - 8. Jeff Stier, National Center for Public Policy Research
  - 9. [Sandra I. Sulsky, Environ](#)
  - 10. Dawn Yrukas
  - 11. Carl V. Philips
  - 12. [Elaine Keller, The Consumer Advocates for Smoke-free Alternatives Association](#)
  - 13. Linc Williams
  - 14. Justin King
  
- J. Meeting Slices – January 20, 2012
  - 1. [Opening Remarks](#)
  - 2. [College Students’ Awareness and Perceptions of Dissolvable Tobacco Products](#)
  - 3. [Survey Findings from Virginia](#)
  - 4. [Proposed Conceptual Framework](#)

IV. Discussion and Recommendations from January 18-20, 2012 Meeting

- A. Questions to the Committee
- B. Transcripts
  - 1. January 18, 2012
  - 2. January 19, 2012
  - 3. January 20, 2012
- C. Summary Minutes
- D. Webcast